Veterinary Medicines

CANIVERM forte, Tableta

Authorised
  • Fenbendazole
  • Pyrantel embonate
  • Praziquantel
Download as PDF

Product identification

Medicine name:
CANIVERM forte, Tableta
Active substance:
  • Fenbendazole
  • Pyrantel embonate
  • Praziquantel
Target species:
  • Dog
  • Other Canids
  • Cat
  • Other Felids
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Fenbendazole
    150.00
    milligram(s)
    /
    1.00
    Tablet
  • Pyrantel embonate
    144.00
    milligram(s)
    /
    1.00
    Tablet
  • Praziquantel
    50.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
    • Other Canids
    • Cat
    • Other Felids
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AC30
Legal status of supply:
This information is not available for this product.
Authorisation status:
  • Valid
Authorised in:
  • Czechia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Bioveta a.s.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta a.s.
Responsible authority:
  • Institute For State Control Of Veterinary Biologicals And Medicaments
Authorisation number:
  • 96/025/01-C/10
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 26/10/2022
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 26/10/2022
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 26/10/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."